Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics disclosed inducement grants of 45,750 stock options and 2,775 RSUs to sixteen newly hired employees under its 2025 Inducement Plan. The options carry a $39.22 exercise price, matching the October 20, 2026 close, with standard four-year vesting.
Key figures
- New hires
- 16
- Rsus granted
- 2775
- Exercise price
- 39.22
- Options granted
- 45750
- Plan reserve increase
- 250000
- Inducement plan share reserve
- 500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.